Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to -$38.4 million.

  • Neurocrine Biosciences' Change in Receivables fell 182000.0% to -$38.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $210.5 million, marking a year-over-year increase of 42889.45%. This contributed to the annual value of $210.5 million for FY2025, which is 42889.45% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Change in Receivables stood at -$38.4 million for Q4 2025, which was down 182000.0% from $132.3 million recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Change in Receivables peaked at $132.3 million during Q3 2025, and registered a low of -$38.4 million during Q4 2025.
  • In the last 4 years, Neurocrine Biosciences' Change in Receivables had a median value of $17.6 million in 2024 and averaged $25.4 million.
  • Examining YoY changes over the last 5 years, Neurocrine Biosciences' Change in Receivables showed a top increase of 92558.14% in 2025 and a maximum decrease of 182000.0% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Change in Receivables stood at -$9.3 million in 2021, then skyrocketed by 330.11% to $21.4 million in 2023, then crashed by 109.35% to -$2.0 million in 2024, then plummeted by 1820.0% to -$38.4 million in 2025.
  • Its Change in Receivables was -$38.4 million in Q4 2025, compared to $132.3 million in Q3 2025 and $79.7 million in Q2 2025.